

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 27, 2025

APC anti-human CD279 (PD-1)

RRID:AB_940475

Type: Antibody

Proper Citation

(BioLegend Cat# 329908, RRID:AB_940475)

Antibody Information

URL: http://antibodyregistry.org/AB_940475

Proper Citation: (BioLegend Cat# 329908, RRID:AB_940475)

Target Antigen: CD279

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: human

Clone ID: Clone EH12.2H7

Antibody ID: AB_940475

Vendor: BioLegend

Catalog Number: 329908

Alternative Catalog Numbers: 329907

Record Creation Time: 20231110T042439+0000

Record Last Update: 20241115T081436+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD279 (PD-1).

No alerts have been found for APC anti-human CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. *Cell metabolism*, 36(1), 176.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

Zhu M, et al. (2024) Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. *Cell reports*, 43(4), 114065.

de Armas LR, et al. (2024) Accelerated CD8+ T cell maturation in infants with perinatal HIV infection. *iScience*, 27(5), 109720.

Nunoya JI, et al. (2024) Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties. *International journal of molecular sciences*, 25(16).

Hu Y, et al. (2024) Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity. *Cell reports. Medicine*, 5(5), 101530.

Zhu X, et al. (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. *Cancer research*, 84(1), 84.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. *Cell reports*, 43(2), 113767.

Tsubouchi A, et al. (2024) Pooled CRISPR screening of high-content cellular phenotypes using ghost cytometry. *Cell reports methods*, 4(3), 100737.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. *Cell reports. Medicine*, 5(2), 101400.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. *Cancer research communications*, 3(8), 1564.

Li J, et al. (2023) TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1. *iScience*, 26(7), 107185.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.

Imai H, et al. (2023) Peripheral T cell profiling reveals downregulated exhaustion marker and increased diversity in lymphedema post-lymphatic venous anastomosis. *iScience*, 26(6), 106822.

Krausgruber T, et al. (2023) Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. *Immunity*, 56(2), 289.

Blaeschke F, et al. (2023) Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. *Cell*, 186(19), 4216.

Luoma AM, et al. (2022) Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. *Cell*, 185(16), 2918.

Cai J, et al. (2021) Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4+ T cells. *eLife*, 10.

Liao JB, et al. (2021) Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. *Journal for immunotherapy of cancer*, 9(9).

Mathewson ND, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. *Cell*, 184(5), 1281.